British Company Unveils Promising Cannabinoid-Based Cancer Therapy

Oxford Cannabinoid Technologies Plc (OCTP), a UK-based company specializing in the development of cannabinoid-based medicines since 2017, announced this week an expansion of its research and development efforts in oncology with a potential new cancer treatment.

The company has identified a potential first-in-class immunotherapy drug that could be taken in tablet form to treat large tumors, offering an alternative to existing treatment methods.

In a press release for investors on Wednesday, July 19, OCTP’s Chief Scientific Officer, Dr. Valentino Parravicini, explained that after analyzing initial data, the team believes the molecule demonstrates “significant potential” in both in vitro (test tube) and in vivo (living organism) studies.

This discovery could pave the way for new, more accessible cancer therapies based on cannabinoids, providing hope for patients seeking alternatives to current treatments.